BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
11/21/2024 7:04:50 AM | Browse: 75 | Download: 248
 |
Received |
|
2024-09-02 23:08 |
|
Peer-Review Started |
|
2024-09-02 23:08 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2024-09-20 00:54 |
|
Revised |
|
2024-10-10 16:26 |
|
Second Decision |
|
2024-11-04 02:40 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2024-11-04 07:14 |
|
Articles in Press |
|
2024-11-04 07:14 |
|
Publication Fee Transferred |
|
2024-11-06 01:05 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2024-11-12 06:24 |
|
Publish the Manuscript Online |
|
2024-11-21 07:04 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Cohort Study |
| Article Title |
Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Jeremy Liu Chen Kiow, Thomas Hoang, Harjot K Bedi, Zhina Majdzadeh Ardekani, Daniel Rosenfeld, Marica Reise-Filteau, Brian Bressler, Yvette Leung and Greg Rosenfeld |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jeremy Liu Chen Kiow, MD, Department of Medicine, Division of Gastroenterology, Montreal University Hospital Centre (CHUM), 1051 Rue Sanguinet, Montreal H2X 3E4, Quebec, Canada. jeremy.liu.chen.kiow@umontreal.ca |
| Key Words |
Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Biologics; Adalimumab; Biosimilar switch |
| Core Tip |
Although there have been several studies evaluating the short-term clinical outcomes of adalimumab (ADA) biosimilar switching, there has been a lack of data assessing the long-term outcomes, especially in Canada. Non-medical switching of the ADA originator to biosimilars did not result in significant differences in treatment persistence, loss of response, or adverse events compared to ADA originator continuation in inflammatory bowel disease (IBD). The findings from this real-world evidence study support the long-term efficacy and safety of non-medical ADA switching in IBD. These data will help inform patients and physicians in jurisdictions currently undergoing biosimilar switching and guide future biosimilar adoption and practice guidelines. |
| Publish Date |
2024-11-21 07:04 |
| Citation |
<p>Liu Chen Kiow J, Hoang T, Bedi HK, Majdzadeh Ardekani Z, Rosenfeld D, Reise-Filteau M, Bressler B, Leung Y, Rosenfeld G. Real-world experience and long-term outcomes of a mandatory non-medical switch of adalimumab originator to biosimilars in inflammatory bowel disease. <i>World J Gastroenterol</i> 2024; 30(46): 4904-4913</p> |
| URL |
https://www.wjgnet.com/1007-9327/full/v30/i46/4904.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v30.i46.4904 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
